Your browser doesn't support javascript.
loading
Intermittent versus continuous administration of pazopanib in progressive radioiodine refractory thyroid carcinoma: Final results of the randomised, multicenter, open-label phase II trial PAZOTHYR.
de la Fouchardière, Christelle; Godbert, Yann; Dalban, Cécile; Illouz, Frédéric; Wassermann, Johanna; Do Cao, Christine; Bardet, Stéphane; Zerdoud, Slimane; Chougnet, Cécile N; Zalzali, Mohamed; Benisvy, Danielle; Niccoli, Patricia; Digue, Laurence; Lamartina, Livia; Schwartz, Paul; Borson Chazot, Françoise; Gautier, Julien; Pérol, David; Leboulleux, Sophie.
Affiliation
  • de la Fouchardière C; Medical Oncology Department, Centre Leon Bérard, Lyon, France. Electronic address: christelle.delafouchardiere@lyon.unicancer.fr.
  • Godbert Y; Nuclear Medicine and Endocrine Oncology Department, Institut Bergonié, Bordeaux, France.
  • Dalban C; Department of Clinical Research and Innovation, Léon Bérard Cancer Center, Lyon, France.
  • Illouz F; Department of Endocrinology, CHU Angers, Angers, France.
  • Wassermann J; Medical Oncology Department and Thyroid Unit, AP-HP, Hôpital Pitié-Salpêtrière, Paris, France.
  • Do Cao C; Department of Endocrinology, Centre Hospitalier Régional Universitaire de Lille, Lille, France.
  • Bardet S; Department of Nuclear Medicine and Thyroid Unit, Centre François Baclesse, Caen, France.
  • Zerdoud S; Department of Nuclear Medicine, Institute Claudius Regaud, Oncology University Institute - IUCT Oncopole, Toulouse, France.
  • Chougnet CN; Endocrine Oncology, Nuclear Medicine Department, Hôpital Saint-Louis, Paris, France.
  • Zalzali M; Department of Endocrinology and Metabolic Disease, Institut Jean Godinot, Reims, France.
  • Benisvy D; Nuclear Medicine Department, Centre Antoine Lacassagne, Nice, France.
  • Niccoli P; Medical Oncology Department, Hôpital la Timone, Marseille, France.
  • Digue L; Medical Oncology Department, CHU Bordeaux, Bordeaux, France.
  • Lamartina L; Department of Nuclear Medicine and Endocrine Oncology, And Université Paris Saclay, Gustave Roussy, Villejuif, France.
  • Schwartz P; Nuclear Medicine and Endocrine Oncology Department, Institut Bergonié, Bordeaux, France.
  • Borson Chazot F; Endocrinology Department, Hospices Civils de Lyon, Hôpital Louis-Pradel, Bron, 69500, France.
  • Gautier J; Department of Clinical Research and Innovation, Léon Bérard Cancer Center, Lyon, France.
  • Pérol D; Department of Clinical Research and Innovation, Léon Bérard Cancer Center, Lyon, France.
  • Leboulleux S; Department of Nuclear Medicine and Endocrine Oncology, And Université Paris Saclay, Gustave Roussy, Villejuif, France.
Eur J Cancer ; 157: 153-164, 2021 11.
Article in En | MEDLINE | ID: mdl-34509954
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyrimidines / Sulfonamides / Thyroid Neoplasms / Indazoles / Iodine Radioisotopes Type of study: Clinical_trials Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Eur J Cancer Year: 2021 Document type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyrimidines / Sulfonamides / Thyroid Neoplasms / Indazoles / Iodine Radioisotopes Type of study: Clinical_trials Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Eur J Cancer Year: 2021 Document type: Article